Stemnovate offers high-quality human iPSC Cell Lines for researchers and scientists. They use these iPSC cell lines in disease modelling and other stem cell research.
The iPS lines show stable expression of core pluripotency genes such as NANOG, TRA 1-60, OCT4, SOX2, LIN28 over several passages and characterisation includes immunochemistry qPCR analyses.
The feeder-free and serum-free conditions help cells to maintain in pluripotent state and long-term storage while frozen below -80ºC or in liquid Nitrogen. Stemnovate has whole-genome transcriptomics and the genotype information for all iPSC lines. In other words, bioinformatic evaluation includes comparative studies to three human embryonic stem cell lines.
Stemnovate iPSCs form embryoid bodies and differentiate into derivatives of the three germ layers in vitro. As a result, IPS on differentiation into embryoid bodies express ECTODERM MESODERM and ENDODERM Markers.
Stemnovate’s Induced pluripotent stem cells (iPSCs) are formed by reprogramming somatic cells such as skin (fibroblast, keratinocytes) or blood (PBMNCs, peripheral blood mononuclear cells). Therefore, iPSCs represent a unique and ethical tool for modelling disease and organ toxicity, with enormous potential for drug discovery and cellular therapies.
The non-integrating method results in stable IPS line generation with high efficiency and reproducibility compared to other viral reprogramming methods. The ability to expand pluripotent cells in vitro and subject them to direct differentiation to produce specific cell types is crucial to developing cell-based therapies to replace or restore tissue.
Stemnovate holds a commercial license from IPS Academia Japan for which Prof. Yamanaka and Prof Gurdon received the Noble prize in 2012 for reprogramming technology.
Stemnovate human iPSC cell lines have been tested negative for HIV-1, HIV-2, Hepatitis-A, Hepatitis-B, bacteria, and mycoplasma.
Stemnovate IPSC lines are capable of differentiating into different organ cells. For instance, functional liver cells (Hepatocytes), heart cells (Cardiomyocytes showing key cardiac markers and beating behaviour), and sensory neurons (showing neuronal marker expression and action potential generation on microelectrode arrays).
Stemnovate does not sell or generate human embryonic stem cell lines. The pre-established HES lines are for research and development purposes only.
|Line History||Caucasian, 22-Year-Old Male|
|Cell Type||Human Fibroblast derived|
|Post Freeze Viability||70-75%|
|Genotype||Data available (request further information)|
|Reprogramming Method||Non-Integrative Episomal|
|Reprogramming Conditions||Feeder Free, Serum Free, derived using morphological selection|
|Inoculation for microbiological growth||Negative|
Stable line characterised for expression of endogenous pluripotency markers, Oct4, Sox2, Nanog, Lin28, Tra1-60, SSEA4.
Transcriptome data available (Request information)
Trilineage Differentiation assessed through spontaneous differentiation to endoderm, ectoderm and mesoderm derivatives
Directed differentiation to Hepatocyte Like Cells-Liver (request more information)